PHATHOM PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $175.1M | $55.3M | $682.0K | $0 | — | — | — |
| Cost of Revenue | — | $22.6M | $8.0M | $167.0K | $0 | — | — | — |
| Gross Profit | — | $152.5M | $47.3M | $515.0K | $0 | — | — | — |
| Gross Margin | — | 87.1% | 85.6% | 75.5% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $32.8M | $34.1M | $49.9M | $71.4M | $72.3M | $98.1M | $20.4M |
| SG&A Expense | — | $279.7M | $290.7M | $117.9M | $101.0M | $62.7M | $27.5M | $6.9M |
| Operating Income | — | $-160.0M | $-277.5M | $-167.3M | $-172.4M | $-135.1M | $-125.7M | $-106.2M |
| Operating Margin | — | -91.4% | -502.2% | -24,532.6% | — | — | — | — |
| Interest Expense | — | — | — | $42.0M | $27.3M | $6.8M | $4.6M | $4.2M |
| Pretax Income | — | $-221.2M | $-334.3M | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-221.2M | $-334.3M | $-201.6M | $-197.7M | $-143.9M | $-129.1M | $-255.1M |
| Net Margin | — | -126.3% | -605.1% | -29,558.9% | — | — | — | — |
| EPS (Basic) | — | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 | $-3.88 | $-22.45 |
| EPS (Diluted) | — | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 | $-3.88 | $-22.45 |
| Shares Outstanding (Basic) | 78.8M | 72.9M | 63.2M | 51.3M | 39.1M | 37.0M | 28.5M | 24.7M |
| Shares Outstanding (Diluted) | 78.8M | 72.9M | 63.2M | 51.3M | 39.1M | 37.0M | 28.5M | 24.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |